251 related articles for article (PubMed ID: 27616574)
1. Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
Wang YQ; Shen AJ; Sun JY; Wang X; Liu HC; Zhang MM; Chen DQ; Xiong B; Shen JK; Geng MY; Zheng M; Ding J
Acta Pharmacol Sin; 2016 Dec; 37(12):1587-1596. PubMed ID: 27616574
[TBL] [Abstract][Full Text] [Related]
2. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
[TBL] [Abstract][Full Text] [Related]
3. Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells.
Yang J; Wu W; Wen J; Ye H; Luo H; Bai P; Tang M; Wang F; Zheng L; Yang S; Li W; Peng A; Yang L; Wan L; Chen L
Biomaterials; 2017 Oct; 141():188-198. PubMed ID: 28689115
[TBL] [Abstract][Full Text] [Related]
4. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Ono N; Yamazaki T; Tsukaguchi T; Fujii T; Sakata K; Suda A; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
[TBL] [Abstract][Full Text] [Related]
6. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer.
Mao J; Ma L; Shen Y; Zhu K; Zhang R; Xi W; Ruan Z; Luo C; Chen Z; Xi X; Chen S
Cell Death Dis; 2018 Sep; 9(10):963. PubMed ID: 30237564
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
Jang WJ; Jung SK; Kang JS; Jeong JW; Bae MK; Joo SH; Park GH; Kundu JK; Hong YS; Jeong CH
Cancer Sci; 2014 Oct; 105(10):1245-53. PubMed ID: 25117641
[TBL] [Abstract][Full Text] [Related]
8. The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
Wang J; Wei H; Zhao B; Li M; Lv W; Lv L; Song B; Lv S
J Mol Histol; 2014 Dec; 45(6):641-52. PubMed ID: 25008024
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Yoshimoto M; Hirata M; Kanai Y; Naka S; Nishii R; Kagawa S; Kawai K; Ohmomo Y
Biol Pharm Bull; 2014; 37(3):355-60. PubMed ID: 24583857
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
Zhang B; Jiao J; Liu Y; Guo LX; Zhou B; Li GQ; Yao ZJ; Zhou GB
PLoS One; 2012; 7(11):e48748. PubMed ID: 23185274
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
12. PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
Zhao XM; Pan SY; Huang QL; Lu YN; Wu XH; Chang JH; Liu ZB; Cai XW; Liu Q; Wang JL; Fu XL
Oncotarget; 2016 Aug; 7(31):49384-49396. PubMed ID: 27283902
[TBL] [Abstract][Full Text] [Related]
13. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
14. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Rice JW; Veal JM; Barabasz A; Foley B; Fadden P; Scott A; Huang K; Steed P; Hall S
Oncol Res; 2009; 18(5-6):229-42. PubMed ID: 20225761
[TBL] [Abstract][Full Text] [Related]
15. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
Choi YJ; Kim SY; So KS; Baek IJ; Kim WS; Choi SH; Lee JC; Bivona TG; Rho JK; Choi CM
PLoS One; 2015; 10(3):e0119832. PubMed ID: 25780909
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Galvani E; Giovannetti E; Saccani F; Cavazzoni A; Leon LG; Dekker H; Alfieri R; Carmi C; Mor M; Ardizzoni A; Petronini PG; Peters GJ
Neoplasia; 2013 Jan; 15(1):61-72. PubMed ID: 23359111
[TBL] [Abstract][Full Text] [Related]
17. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
Li X; Fan XX; Jiang ZB; Loo WT; Yao XJ; Leung EL; Chow LW; Liu L
Pharmacol Res; 2017 Jan; 115():45-55. PubMed ID: 27864022
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
Hong YS; Jang WJ; Chun KS; Jeong CH
Oncol Rep; 2014 Jun; 31(6):2619-24. PubMed ID: 24789511
[TBL] [Abstract][Full Text] [Related]
19. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Jung SK; Lee MH; Lim DY; Lee SY; Jeong CH; Kim JE; Lim TG; Chen H; Bode AM; Lee HJ; Lee KW; Dong Z
Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831
[TBL] [Abstract][Full Text] [Related]
20. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
